Organization | Dutch Society of Physicians for Pulmonology and Tuberculosis

Dutch Society of Physicians for Pulmonology and Tuberculosis Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2009

NCT00835471

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Dutch Society of Physicians for Pulmonology and Tuberculosis

Active Ingredients

Drugs in Phase 3 Trials (9)

bevacizumab (avastin) (2 trials)

carboplatin (paraplatin) (2 trials)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (2 trials)

durvalumab (imfinzi) (1 trial)

erlotinib (tarceva) (2 trials)

paclitaxel (taxol) (2 trials)

pembrolizumab (keytruda) (1 trial)

pemetrexed (alimta) (2 trials)

Drugs in Phase 2 Trials (1)

nitroglycerin (transderm-nitro) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 10